Clinical Trial Update: A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating safety, tolerability, and pharmacokinetics of a single IV dose of rFVIIIFc-VWF-XTEN (BIVV001) in previously treated adults with sever…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• rFVIIIFc-VWF-XTEN (BIVV001)

Snippet

Sponsor: Bioverativ, a Sanofi company | Conditions: Hemophilia A | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-12-02